Last reviewed · How we verify

NCT04915963

Vitamin D Supplementation in Intensive Care Unit Patients

Completed Phase 3 Last updated 18 June 2021
What this trial tests

Phase 3 trial testing Vitamin D supplementation in Dietary Supplements in 340 participants. Completed in 30 May 2019.

Timeline
20 January 2016
Primary endpoint
10 March 2019
30 May 2019

Quick facts

Lead sponsorAssociation Tunisienne d'Etude & de Recherche sur l'Athérosclérose
PhasePhase 3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposesupportive care
Enrollment340
Start date20 January 2016
Primary completion10 March 2019
Estimated completion30 May 2019

Drugs / interventions tested

Conditions studied

Sponsor

Association Tunisienne d'Etude & de Recherche sur l'Athérosclérose

Who can join

19 and older, any sex, with Dietary Supplements or Intensive Care Unit. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A randomized controlled trial is designed to investigate the safety and clinical efficacy of a mega dose of VD in patients admitted in intensive care unit (ICU). Patients will be randomly allocated to receive 400,000 IU of VD3 or placebo. They will be followed up until ICU discharge or death or the 15th day of ICU stay. Adverse events that occur during ICU stay is collected. Primary outcome is intensive care unit-acquired infection (ICU-AI), and secondary outcomes are septic shock, organ failure, and ICU-mortality. Plasma 25-hydroxyvitamin D is assessed at baseline and at the end of follow-up. Cox regression models will be applied to test how VD supplementation affects adverse outcomes while adjusting for confounders.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Vitamin D supplementation

Trials testing the same drug.

Other recruiting trials for Dietary Supplements

Currently open trials in the same condition.

Other Association Tunisienne d'Etude & de Recherche sur l'Athérosclérose trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04915963.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing